The company is pleased to announce recent seed grant approval from the Maine Technology Institute (MTI). The award will be used to develop a proof-of-concept prototype designed to extend the feature set of the company’s core product, the ETF. Much of the work will be done in collaboration with the University of Maine’s Department of Chemical and Biomedical Engineering. Funding will also cover patent filing on the novel prototype.”We’re excited to work with MTI and UMaine to push the boundaries of clinical care diagnostics.” said company CEO, Todd O’Brien. ” The extended capabilities we’re developing for the ETF will provide a unique approach for assessing neuropathy in a point-of-care setting”.
Large fiber peripheral neuropathy (PN) impairing somatosensory feedback and normal motor responses can occur in a variety of diseases. It is generally acknowledged that most elderly patients will have some loss of peripheral neurological function though it is seldom formally diagnosed. This age-related or “senescent” form of neuropathy can result in the same loss of large fiber nerve function as its better known correlate diabetic PN (DPN).
Regardless of the cause, large fiber PN can result in loss of proprioception, touch, vibratory sensation and muscle strength. These impairments can result in balance and postural control deficits predisposing patients to falls. Falls have long been acknowledged as a major healthcare issue affecting elderly and diabetic patients at higher rates than the general population. Large fiber PN has been determined to be a significant contributor to these falls. Recent research reveals that assessement of the Vibration Perception Threshold (VPT), equivalent to the 25v setting on the standard Biothesiometer, is an effective PN screening method for a Fall Risk Assessment protocol among elderly patients.
In light of these recommendations, the ETF can be seen as an appropriate choice when considering methods of performing recommended screening tests as part of a Fall Risk Assessment. This feature is available in the Contant Mode which provides the same vibration as the Biothesiometer at the 25v level. Using the ETF in Constant Mode, the patient can simply give a “yes” or “no” answer as to whether or not they feel the vibration. Superior portability and ease of use make the ETF ideally suited to point-of-care VPT screening in clinics and hospitals when evaluating patients for fall risk.